Akums Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26
Akums Drugs and Pharmaceuticals Ltd · Outcome · 02 Nov 2026, 10:44 pm
Akums Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 13,424 (+31.9% YoY | +15.1% QoQ) ■ EBITDA: 1,947 (+106.1% YoY | +11.5% QoQ) ■ EBITDA Margin (%): 14.5 (+522 bps YoY | -47 bps QoQ) ■ PAT: 1,129 (+176.7% YoY | +12.8% QoQ) ■ EPS (INR): 7.37 (+177.1% YoY | +12.9% QoQ) Akums Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance CDMO ■ Revenue: 11,149 (+38.6% YoY | +15.6% QoQ) ■ EBITDA: 1,682 (+99.6% YoY | +2.9% QoQ) ■ EBITDA Margin (%): 15.1 (+461 bps YoY | -186 bps QoQ) API ■ Revenue: 288 (-35.3% YoY | -9.1% QoQ) ■ EBITDA: -57.4 (+59.1% YoY | -47.1% QoQ) ■ EBITDA Margin (%): -20.0 (+1160 bps YoY | -762 bps QoQ) Domestic branded formulations ■ Revenue: 1,319 (+8.2% YoY | +14.4% QoQ) ■ EBITDA: 240 (-8.9% YoY | +103.2% QoQ) ■ EBITDA Margin (%): 18.2 (-342 bps YoY | +796 bps QoQ) International branded formulations ■ Revenue: 438 (+95.2% YoY | +26.7% QoQ) ■ EBITDA: 99.1 (+80.5% YoY | +43.8% QoQ) ■ EBITDA Margin (%): 22.6 (-184 bps YoY | +268 bps QoQ) Trade generics ■ Revenue: 231 (-5.4% YoY | +10.1% QoQ) ■ EBITDA: 11.9 (Loss to Profit YoY | +746.4% QoQ) ■ EBITDA Margin (%): 5.1 (Loss to Profit YoY | +447 bps QoQ)
Original exchange filing (PDF)
More announcements from Akums Drugs and Pharmaceuticals Ltd
- Intimation of Schedule of the Investors/Analysts Meet · 10 Nov 2026
- Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026 · 05 Nov 2026
- Audio recording of Earning/ Quarterly Conference Call · 03 Nov 2026
- Newspaper Publication · 03 Nov 2026
- Final Report of CRISIL Ratings Limited, Monitoring Agency · 03 Nov 2026
- Q2 FY 2026-27 - Investor Presentation · 02 Nov 2026
- Press Release · 02 Nov 2026
- Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company. · 02 Nov 2026
